Apriori Bio

We recently caught up with Director of Data Science Max Winston, PhD, to hear how he is leading our team of data scientists as we advance our Octavia™ platform. “The vision we are working towards—providing humanity with variant-resilient protection against rapidly evolving viruses—is ambitious and involves everyone at Apriori. I am inspired by our team, the collaborative environment we’re building, and the progress we’re making on a daily basis,” he said. Read our full Q&A with Max below. #AprioriLife #WeAreHiring #JoinUs

Join us in welcoming Harry Kleanthous to the Apriori team as our Chief Scientific Officer. Harry's 30+ years of experience and leadership at biotech and large biopharma companies will be a tremendous asset as we work to better protect humanity against rapidly-evolving viruses.      Learn more about what he brings to our team: https://lnkd.in/e8e-c6GV #FlagshipFounded

Apriori President Craig Williams recently joined other global healthcare leaders on a panel at the UNGA Science Summit 2024 to discuss pandemic preparedness and the importance of data to improve decision-making and global health outcomes. Craig spoke about our work to help provide humanity with variant-resilient protection against rapidly-evolving viruses, and the need to invest in infrastructure now to prevent future pandemics.    Thank you to Airfinity Ltd for organizing this important conversation. #SSUNGA79 #FlagshipFounded

We're pleased to welcome Seth Berkley, Arup Chakraborty, and Ashish Jha to our Board of Directors. These world-class vaccine, immunology, and public health leaders will join Board Chair Lovisa Afzelius and Travis Wilson, Growth Partner at Flagship Pioneering, in supporting our leadership team as they advance our mission to protect humanity against viral threats.    Their expertise in vaccine development and public health will be instrumental as we expand our biology-informed AI platform, Octavia™, to develop variant-resilient protection against rapidly-evolving viruses.    Read the full press release to learn more: https://lnkd.in/ePXt6s_r #FlagshipFounded

Citeline’s Eliza Slawther wrote about how Apriori is leading the way in vaccine development by leveraging AI and machine learning to design variant-resilient vaccines.    Our CEO Lovisa Afzelius commented on the importance of shifting away from the reactive way in which vaccines have previously been developed and distributed. Read more about how we are using our platform Octavia™ to get ahead of future viral outbreaks: https://lnkd.in/ekYzn7zd

Proactively protecting health through preemptive medicine is a key pillar of our work at Apriori. We are excited to work with Raj Panjabi as he steps in to lead the Preemptive Health and Medicine Initiative at Flagship Pioneering. He has deep experience, both as a physician and serving in the Biden administration, tackling some of the world’s biggest public health challenges. His insights will help us develop variant-resilient vaccines to protect humanity against viral threats.

Members of our team and their families joined our CEO Lovisa Afzelius and president Craig Williams for a picnic to celebrate summer and our milestones this year. It was fun to connect outside of the office! 

Today is an exciting day to be a #FlagshipFounded company as Flagship Pioneering announces a $3.6 billion fund to further transform human health. This commitment to innovation is the latest example of the bold scientific leaps we, and other companies across the ecosystem, are taking to advance scientific breakthroughs. For our part, we look forward to continuing our work to protect humanity against future viral threats and we look forward to seeing the new innovations supported by this fund.

We are pleased to announce that we have been awarded funding from CEPI (Coalition for Epidemic Preparedness Innovations), a global leader in pandemic preparedness, to help advance our biology-informed #artificialintelligence platform Octavia™. The insights we gather from Octavia will help to ensure the global community is better prepared to effectively address future outbreaks with precision and speed. Through this work, we aim to develop variant-resilient vaccines that remain protective for years to come, with an initial focus on further exploring pandemic influenza strain H3N2. Read more about how these funds will help advance our platform and our mission to protect humanity against future viral threats: https://lnkd.in/eX-Yrr47

We recently spoke with senior scientist Nicole Thadani, PhD, about her background and deep interest in human immunology, and how she learned about Apriori from the research of Apriori scientific advisor Jesse Bloom, PhD. “We’re at this pivotal moment where society has recognized how much pandemics can shape our lives. It’s a great time to take advantage of the investment society is willing to make to better prepare to address the next one,” she shared. Read our full Q&A with Nicole below. #AprioriLife #WeAreHiring #JoinUs